Lonza Group AG stock (CH0013841017): Pharma services group outlines reset after 2024 profit warning

Lonza Group AG remains in focus after its 2024 profit warning and subsequent strategic reset in biologics manufacturing and capsules. The Swiss life-sciences supplier is working through contract losses while investing in new capacity, a combination closely watched by global and US healthcare investors.

Lonza Group AG continues to draw investor attention in 2026 as the Swiss contract development and manufacturing organization (CDMO) executes a strategic reset following a 2024 profit warning tied to weaker demand and contract adjustments in its biologics and capsules businesses, according to company statements and financial filings published in 2024 and 2025 by Lonza and major business media.

Lonza reported that 2024 results were pressured by lower volumes and the non-renewal or reshaping of certain large contracts, particularly in biologics and small molecules, prompting a review of its growth investments and cost structure, as described in its 2024 full-year reporting released in early 2025, according to Lonza investor relations as of 02/12/2025.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza
• Sector/industry: Life sciences, contract drug development and manufacturing (CDMO)
• Headquarters/country: Basel, Switzerland
• Core markets: Biopharmaceutical and healthcare customers in Europe, the United States and Asia
• Key revenue drivers: Biologics CDMO services, small molecules, capsules and specialty ingredients for pharma and nutrition
• Home exchange/listing venue: SIX Swiss Exchange (ticker: LONN)
• Trading currency: Swiss franc (CHF)

Lonza Group AG: core business model

Lonza Group AG is a global CDMO that provides development, manufacturing and related services for pharmaceutical, biotech and healthcare companies. The group works across the value chain, from early-stage process development to commercial-scale production of biologics, small molecule drugs and cell and gene therapies. It also supplies capsules and ingredients for pharma and nutrition applications, according to Lonza about page as of 03/05/2025.

The company historically organized its activities into segments such as Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Biologics, including mammalian and microbial manufacturing, has been a major growth engine in recent years thanks to strong demand for monoclonal antibodies and other complex modalities. Capsules & Health Ingredients covers hard gelatin capsules, specialty dosage forms and related ingredients for both prescription medicines and consumer health products.

Lonza creates value by enabling pharmaceutical and biotech clients to outsource complex development and manufacturing steps rather than building and operating their own large-scale facilities. This outsourced model is particularly relevant for smaller biotech firms that lack manufacturing infrastructure, as well as for large pharmaceutical companies looking to increase flexibility and manage capital intensity in areas such as biologics and cell therapies.

The group has a broad global footprint with production sites in Europe, North America and Asia, including major facilities in Switzerland, the United States and Singapore. For US-based investors, the company’s presence in key American biotech hubs and its role in manufacturing therapies destined for the US health-care market help link Lonza’s performance to the broader US biotech and pharmaceutical cycle, according to Lonza reports and news as of 11/15/2024.

Main revenue and product drivers for Lonza Group AG

Biologics CDMO activities are a primary revenue driver for Lonza. This business provides manufacturing capacity for therapeutic proteins, monoclonal antibodies and other advanced biologics. Large biopharma companies use Lonza’s services to secure additional capacity and diversify their supply chains, while smaller biotech firms depend on the company’s expertise and infrastructure to bring their candidates through clinical trials and into commercialization.

Beyond biologics, Lonza generates revenue from small molecule development and manufacturing, including active pharmaceutical ingredients for a variety of therapies. This segment benefits from long-term contracts and technical capabilities in complex chemistry, helping support more stable demand across economic cycles. Trends such as the continued need for specialty small molecules in oncology and central nervous system disorders underpin the segment’s relevance.

Capsules and related health ingredients represent another important pillar for Lonza. Through well-known capsule brands and technologies, the company supplies dosage forms to pharmaceutical companies, generics manufacturers and over-the-counter product makers. Demand in this area is driven by the overall volume of oral solid dose medications and supplements, along with customer preferences for specialized delivery systems such as vegetarian capsules or targeted release formulations.

In recent years, Lonza has also invested in newer areas like cell and gene therapy manufacturing. While still a smaller part of group revenue compared to biologics and capsules, this activity is closely watched by investors because it could represent a long-term growth vector if more advanced therapies receive regulatory approval. The company’s ability to provide end-to-end solutions in these high-complexity areas is a point of differentiation versus some competitors in the CDMO space.

Conclusion

Lonza Group AG sits at the intersection of global pharma outsourcing, with biologics, small molecules and capsules as its main revenue engines. The company’s 2024 profit warning and subsequent strategic reset underscored the cyclical and contract-driven nature of its markets, but also highlighted the long-term structural demand for CDMO capacity. For US-focused investors, Lonza’s exposure to American biotech and pharma customers, its broad service offering and its investments in newer modalities provide a mix of opportunities and risks that will likely remain in focus as management executes its multi-year strategy.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.